Novo Nordisk's CagriSema Beats Tirzepatid in Head-to-Head Trial, Yet Shares Slide as London Strategy Day Disappoints
Published on 09/22/2026 at 05:20 | Editorial boerse-global.de
Novo Nordisk delivered compelling clinical evidence for its next-generation obesity candidate on Monday, but the data failed to lift investor sentiment as management's long-range targets at its Capital Markets Day in London drew a lukewarm reception.
In the REIMAGINE 5 phase-3 study, once-weekly CagriSema at a dose of 1.0 mg/1.0 mg produced an estimated average weight loss of 12.4%, outpacing the 9.1% reduction achieved by patients on 5 mg of rival therapy Tirzepatid over the same period. A second trial, REDEFINE 9, reinforced the drug's profile: participants on CagriSema shed an average of 21.0% of their body weight, compared with just 2.0% in the placebo arm.
Those results underscore the clinical strength of the company's combined-mechanism platform. The Danish drugmaker intends to roll out successive generations of obesity therapies, starting with CagriSema, followed by high-dose formulations and the compounds Cagrilintid and Zenagamtide.
Market Skepticism Overrides Pipeline Momentum
Despite the encouraging trial readouts, the stock came under heavy selling pressure. Shares fell 7.5% to EUR 34.79 on Monday, extending a year-to-date decline that now stands at 21%. The previous session had already seen a 7.4% drop to EUR 34.84.
At the London event, CEO Mike Doustdar addressed the company's principal medium-term challenges. Chief among them is the gradual expiration of patent protection for semaglutide — the active ingredient behind Wegovy and Ozempic — particularly in the US, which accounts for more than half of group revenues. American exclusivity for semaglutide runs until 2032.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
For the 2026–2030 window, Novo Nordisk is targeting revenue growth in line with the industry average, while aiming to treat more than 60 million patients worldwide by 2030. Management also plans to introduce more than five new blockbuster medicines by the end of the decade, with pipeline revenues projected to exceed DKK 150 billion by 2035.
To protect profitability, the company is continuously adjusting its cost structures. The operating margin is to be kept at a broadly stable level despite shifting market dynamics, complemented by an attractive dividend per share.
Analysts and market participants, however, responded cautiously to these projections, according to Reuters. Concerns centered on future pricing power, potential acquisitions, and the looming patent cliff for semaglutide. Sentiment had already soured earlier: on 11 September, Morgan Stanley downgraded the stock from Equal-weight to Underweight, maintaining a price target of DKK 250, citing muted medium-term growth prospects and heavy reliance on the semaglutide franchise ahead of patent expirations.
Buybacks, Rebranding and a Packed Deal Calendar
While the share price struggled, Novo Nordisk continued to lean on share repurchases to support its capital structure. Since early February, the group has bought back more than 34 million of its own B-shares, deploying roughly DKK 9.63 billion in transaction funds. The ongoing program runs alongside a sharpened organizational setup that includes a revised public-facing identity: in day-to-day operations the company now trades under the name Novo, while Novo Nordisk A/S remains its legal designation.
The company has also moved quickly to broaden its pipeline beyond existing blockbusters. On Thursday, it entered a development and licensing agreement with Orbis Medicines focused on oral cardiometabolic therapies. Orbis valued the total deal at up to USD 1.4 billion, comprising upfront and milestone payments, tiered royalties, and a strategic equity stake held by Novo Nordisk. A day earlier, Novo Nordisk announced a collaboration with Anthropic to accelerate drug development and biological analysis through artificial intelligence.
Regulatory Wins in Europe
On the regulatory front, the company picked up twin endorsements from the European Medicines Agency's Committee for Medicinal Products for Human Use. On Friday, the panel recommended approval for once-weekly Sogroya in children with persistent growth disorders, including idiopathic short stature. The prior Thursday, the same committee issued a positive opinion for the hemophilia treatment FREHEMGO.
The clinical advances and dealmaking activity stand in contrast to a period of elevated strategic transition risk, with investors clearly weighing near-term uncertainty more heavily than pipeline promise.
Ad
Novo Nordisk Stock: New Analysis - 22 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
